Evidence map›Paper›PMID 33341248›Full record

ReviewTrends in pharmacological sciences2021

Organ-on-a-Chip: A New Paradigm for Drug Development.

Chao Ma, Yansong Peng, Hongtong Li, Weiqiang Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in pharmacological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 271 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chao MaDepartment of Mechanical and Aerospace Engineering, New York University, Brooklyn, NY 11201, USA; Department of Biomedical Engineering, New York University, Brooklyn, NY 11201, USA.
Yansong PengDepartment of Biomedical Engineering, New York University, Brooklyn, NY 11201, USA.
Hongtong LiDepartment of Mechanical and Aerospace Engineering, New York University, Brooklyn, NY 11201, USA.
Weiqiang ChenDepartment of Mechanical and Aerospace Engineering, New York University, Brooklyn, NY 11201, USA; Department of Biomedical Engineering, New York University, Brooklyn, NY 11201, USA; Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA. Electronic address: wchen@nyu.edu.

Funding

Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell ImmunotherapyR01CA243001 · NCI · NEW YORK UNIVERSITY · PI CHEN, PENGYU, CHEN, WEIQIANG · 2020 to 2024
$2.6M
Purchase of spinning disk confocal microscopeR35GM133646 · NIGMS · NEW YORK UNIVERSITY · PI CHEN, WEIQIANG · 2019 to 2023
$2.0M
Engineered Glioblastoma Tumor Immunity for Personalized ImmunotherapyR21EB025406 · NIBIB · NEW YORK UNIVERSITY · PI CHEN, WEIQIANG, SNUDERL, MATIJA · 2018 to 2020
$610k
NCI NIH HHS R01 CA243001NIBIB NIH HHS R21 EB025406NIGMS NIH HHS R35 GM133646
6 · The paper itself

Abstract

The pharmaceutical industry has been desperately searching for efficient drug discovery methods. Organ-on-a-Chip, a cutting-edge technology that can emulate the physiological environment and functionality of human organs on a chip for disease modeling and drug testing, shows great potential for revolutionizing the drug development pipeline. However, successful translation of this novel engineering platform into routine pharmacological and medical scenarios remains to be realized. In this review, we discuss how the Organ-on-a-Chip technology can have critical roles in different preclinical stages of drug development and highlight the current challenges in translation and commercialization of this technology for the pharmacological and medical end-users. Moreover, this review sheds light on the future developmental trends and need for a next-generation Organ-on-a-Chip platform to bridge the gap between animal studies and clinical trials for the pharmaceutical industry.

Indexed as

Drug DevelopmentLab-On-A-Chip DevicesAnimalsDrug DiscoveryDrug IndustryHumansdrug developmentmicrofluidicsmicrophysiological systemOrgan-on-a-Chipprecision medicine

Identifiers

PMID33341248
PMCPMC7990030

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.